Mobile Marketing Platform YouAppi and Xsolla Announce a New Program to Help Mobile Game Developers Grow Their Business
24.5.2023 11:00:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, announced today that they are launching a partnership with YouAppi, the leading mobile marketing platform for global brands wanting to grow their business. The collaboration aims to address the needs of the gaming market by providing retargeting campaigns that help mobile game developers and publishers drive more players to a web shop and grow revenue from existing players.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005134/en/
Mobile Advertising With YouAppi (Graphic: Business Wire)
YouAppi and Xsolla's partnership will transform the game industry business and portfolio strategies for revenue growth and retention to their partners. Xsolla and YouAppi joined forces to help video game developers and publishers retain, retarget and re-engage mobile app users and to amplify what Xsolla Web Shop already does well - it helps to increase the average purchase amount, the number of repeated purchases and re-engage with consumers who have not recently played the game.
"Today, we're proud to announce a game-changing alliance between Xsolla and YouAppi, the leading mobile marketing platform for brands seeking exponential growth, said Chris Hewish, President of Xsolla. "Our joint mission is to revolutionize how video game developers and publishers engage with mobile app users, optimizing retention, retargeting, and re-engagement strategies. By synergizing our efforts, we're amplifying the strengths of Xsolla Web Shop, which already excels in boosting average purchase amounts, repeat purchases, and transitioning traffic from mobile to web."
Web Shop is a direct-to-consumer commerce solution powered by Xsolla for mobile games. Sell in-game items, currencies, and top-up player accounts online, inspire players to purchase, keep more of your revenue, and boost LTV and ARPU, all from your website.
"The Xsolla and YouAppi partnership is a powerful combination. Xsolla's understanding of increasing user monetization through its Web Shop uniquely complements YouAppi's ability to increase user retention through mobile app retargeting," said Moshe Vaknin, CEO of YouAppi. "This will be an industry-leading collaboration."
For more information about the Mobile Advertising platform, please visit: https://xsolla.pro/youappi
About YouAppi
YouAppi is a leading growth and retention platform for mobile apps, specializing in re-engagement and retargeting. Powered by machine learning and audience targeting, YouAppi’s proven proprietary app remarketing technology finds and retains the most profitable users for its clients. YouAppi works with mobile app companies across the globe in gaming, e-commerce, entertainment, lifestyle, and finance among others. Established in 2011, YouAppi has been a long-term partner to leading mobile advertisers, earning recent awards including top 100 fastest-growing companies in North America on the 2021 Deloitte Technology Fast 500™ and 2023 Inc. 5000 Regionals: Pacific list. YouAppi is also ranked a global top 10 remarketing company on the Appsflyer 2022 performance index in gaming and non-gaming. To learn more, visit: www.youappi.com.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, Beijing, Kuala Lumpur, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005134/en/
Contact information
Derrick Stembridge
Global Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom